Premium
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting
Author(s) -
Soucie J. Michael,
Miller Connie H.,
Kelly Fiona M.,
Aschman Diane,
DiMichele Donna,
Konkle Barbara A.,
Kulkarni Roshni,
Monahan Paul E.
Publication year - 2014
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23704
Subject(s) - government (linguistics) , medicine , disease control , family medicine , business , public relations , environmental health , political science , philosophy , linguistics
On March 12, 2012, the Centers for Disease Control and Prevention (CDC) held a meeting of its partners in hemophilia treatment, community‐based organizations, industry, and government to review data and discuss implementation issues relevant to planned United States (U.S.) national inhibitor surveillance. Issues discussed included the current status of inhibitor surveillance in the United Kingdom (UK) and the US, the results of a US inhibitor surveillance feasibility study, proposed national surveillance schemes, laboratory testing and reporting issues and potential opportunities for future inhibitor‐related research. It was concluded that implementation of a national program of inhibitor surveillance using standardized testing through an established public health registry along with patient and care provider education and targeted research provide the best opportunity to inform efforts to develop and evaluate effective prevention strategies.Am. J. Hematol. 89:621–625, 2014. © 2014 Wiley Periodicals, Inc.